These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 22431669

  • 41. HIV type-1 genotypic resistance profiles in vertically infected patients from Argentina reveal an association between K103N+L100I and L74V mutations.
    Aulicino PC, Rocco CA, Mecikovsky D, Bologna R, Mangano A, Sen L.
    Antivir Ther; 2010; 15(4):641-50. PubMed ID: 20587857
    [Abstract] [Full Text] [Related]

  • 42. Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors.
    Poveda E, de Mendoza C, Martin-Carbonero L, Corral A, Briz V, González-Lahoz J, Soriano V.
    J Antimicrob Chemother; 2007 Oct; 60(4):885-8. PubMed ID: 17646201
    [Abstract] [Full Text] [Related]

  • 43. Discordant genotypic interpretation and phenotypic role of protease mutations in HIV-1 subtypes B and G.
    Santos AF, Abecasis AB, Vandamme AM, Camacho RJ, Soares MA.
    J Antimicrob Chemother; 2009 Mar; 63(3):593-9. PubMed ID: 19136678
    [Abstract] [Full Text] [Related]

  • 44. Prediction of early and confirmed virological response by genotypic inhibitory quotients for lopinavir in patients naïve for lopinavir with limited exposure to previous protease inhibitors.
    Torti C, Uccelli MC, Quiros-Roldan E, Gargiulo F, Tirelli V, Lapadula G, Regazzi M, Pierotti P, Tinelli C, De Luca A, Patroni A, Manca N, Carosi G.
    J Clin Virol; 2006 Apr; 35(4):414-9. PubMed ID: 16280255
    [Abstract] [Full Text] [Related]

  • 45. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.
    Walmsley S, Bernstein B, King M, Arribas J, Beall G, Ruane P, Johnson M, Johnson D, Lalonde R, Japour A, Brun S, Sun E, M98-863 Study Team.
    N Engl J Med; 2002 Jun 27; 346(26):2039-46. PubMed ID: 12087139
    [Abstract] [Full Text] [Related]

  • 46. Susceptibility to PNU-140690 (Tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors.
    Rusconi S, La Seta Catamancio S, Citterio P, Kurtagic S, Violin M, Balotta C, Moroni M, Galli M, d'Arminio-Monforte A.
    Antimicrob Agents Chemother; 2000 May 27; 44(5):1328-32. PubMed ID: 10770770
    [Abstract] [Full Text] [Related]

  • 47. Absence of resistance mutations in antiretroviral-naive patients treated with ritonavir-boosted saquinavir.
    Ananworanich J, Hirschel B, Sirivichayakul S, Ubolyam S, Jupimai T, Prasithsirikul W, Chetchotisakd P, Kiertiburanakul S, Munsakul W, Raksakulkarn P, Tansuphasawadikul S, Schutz M, Snowden W, Ruxrungtham K, Staccato Study Team.
    Antivir Ther; 2006 May 27; 11(5):631-5. PubMed ID: 16964832
    [Abstract] [Full Text] [Related]

  • 48. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV.
    Pulido F, Arribas JR, Delgado R, Cabrero E, González-García J, Pérez-Elias MJ, Arranz A, Portilla J, Pasquau J, Iribarren JA, Rubio R, Norton M, OK04 Study Group.
    AIDS; 2008 Jan 11; 22(2):F1-9. PubMed ID: 18097218
    [Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine/lamivudine nucleoside regimen.
    Cameron DW, Becker S, King MS, da Silva B, Klein C, Tokimoto D, Foit C, Calhoun D, Bernstein B, Hanna GJ.
    J Antimicrob Chemother; 2007 May 11; 59(5):957-63. PubMed ID: 17350990
    [Abstract] [Full Text] [Related]

  • 52. A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance.
    Muzammil S, Ross P, Freire E.
    Biochemistry; 2003 Jan 28; 42(3):631-8. PubMed ID: 12534275
    [Abstract] [Full Text] [Related]

  • 53. [Resistance to darunavir].
    García Deltoro M.
    Enferm Infecc Microbiol Clin; 2008 Oct 28; 26 Suppl 10():51-60. PubMed ID: 19195460
    [Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. Genotypic resistance to lopinavir and fosamprenavir with or without ritonavir of clinical isolates from patients failing protease inhibitors-containing HAART regimens: prevalence and predictors.
    Di Giambenedetto S, Bacarelli A, Pinnetti C, Colafigli M, Prosperi M, Gatti G, Cauda R, De Luca A.
    Scand J Infect Dis; 2007 Oct 28; 39(9):813-8. PubMed ID: 17701721
    [Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. Virological response to darunavir in patients infected with HIV is linked to darunavir resistance-associated mutations corrected by the count of mutations with positive impact and is not associated with pharmacological and combined virological/pharmacological parameters.
    Dailly E, Rodallec A, Allavena C, Deslandes G, Garnier E, Billaud E, Ferré V, Reliquet V, Bouquié R, Raffi F, Jolliet P.
    Fundam Clin Pharmacol; 2012 Aug 28; 26(4):538-42. PubMed ID: 21545648
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.